Ganovo+ritonavir+/-Interferon nebulization — Competitive Intelligence Brief

Ganovo+ritonavir+/-Interferon nebulization (Ganovo+ritonavir+/-Interferon nebulization) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Infectious Disease / Virology.

marketed Antiviral combination therapy Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors Infectious Disease / Virology Small molecule

Target snapshot

Ganovo+ritonavir+/-Interferon nebulization (Ganovo+ritonavir+/-Interferon nebulization) — The Ninth Hospital of Nanchang. This combination therapy uses Ganovo (an antiviral nucleoside analog) with ritonavir (a protease inhibitor booster) and optional interferon nebulization to inhibit viral replication and enhance immune response.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ganovo+ritonavir+/-Interferon nebulization TARGET	Ganovo+ritonavir+/-Interferon nebulization	The Ninth Hospital of Nanchang	marketed	Antiviral combination therapy	Viral RNA-dependent RNA polymerase; CYP3A4 (ritonavir); Interferon-alpha/beta receptors
Pegylated interferon alfa-2a + Ribavirin	Pegylated interferon alfa-2a + Ribavirin	University of California, San Francisco	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
D: Peg-interferon alpha-2a & Ribavirin	D: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
F: Peg-interferon alpha-2a & Ribavirin	F: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + LD RBV for 16 weeks	Peg-IFN + LD RBV for 16 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon alpha receptor; HCV RNA polymerase
C: Peg-interferon alpha-2a & Ribavirin	C: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg interferon + Ribavirin	Peg interferon + Ribavirin	University of Valencia	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
2. National Taiwan University Hospital · 6 drugs in this class
3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
4. Hepatitis Resource Network · 1 drug in this class
5. Hospices Civils de Lyon · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Pacific Health Foundation · 1 drug in this class
8. RedHill Biopharma Limited · 1 drug in this class
9. Sherief Abd-Elsalam · 1 drug in this class
10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class